Ensemble Discovery Completes $15 Million Financing

Cambridge-based Ensemble Discovery, which is developing therapeutics and bioassays using its proprietary “DNA-programmed chemistry” platform, has completed a $15 million Series B funding round, PE Week reported. The three-year-old company received a first tranche payment of $10 million back in January, with the remainder just announced. Participants in the round included Aeneas Venture (Harvard Management Company), ARCH Venture Partners, Boston University Technology Development Fund, CMEA Ventures, Flagship Ventures, Harris & Harris Group, and Oxford Bioscience Partners.

Bob is Xconomy's founder and chairman. You can email him at bbuderi@xconomy.com. Follow @bbuderi

Trending on Xconomy